Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cryofocus Medtech (Shanghai) Co Ltd stock PB Ratio (=9.13) is close to 5-year low of 8.65.
The historical rank and industry rank for Cryofocus Medtech (Shanghai) Co's PB Ratio or its related term are showing as below:
HKSE:06922'
s PB Ratio Range Over the Past 10 Years
Min: 8.47 Med: 15.92 Max: 29.52
Current: 9
During the past 6 years, Cryofocus Medtech (Shanghai) Co's highest PB Ratio was 29.52. The lowest was 8.47. And the median was 15.92.
HKSE:06922's PB Ratio is ranked worse than 90.05% of 784
companies
in the Medical Devices & Instruments industry
Industry Median: 2.13
vs HKSE:06922: 9.00
During the past 12 months, Cryofocus Medtech (Shanghai) Co's average Book Value Per Share Growth Rate was -30.30% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -40.90% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -10.10% per year.
During the past 6 years, the highest 3-Year average Book Value Per Share Growth Rate of Cryofocus Medtech (Shanghai) Co was 43.70% per year. The lowest was -40.90% per year. And the median was -27.70% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Cryofocus Medtech (Shanghai) Co PB Ratio Related Terms
Cryofocus Medtech (Shanghai) Co PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Cryofocus Medtech (Shanghai) Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cryofocus Medtech (Shanghai) Co PB Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Cryofocus Medtech (Shanghai) Co's PB Ratio distribution charts can be found below:
* The bar in red indicates where Cryofocus Medtech (Shanghai) Co's PB Ratio falls into.
Cryofocus Medtech (Shanghai) Co PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Cryofocus Medtech (Shanghai) Co (HKSE:06922) has a PB Ratio of 8.97 as of Sep. 09, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Cryofocus Medtech (Shanghai) Co and its competitors. This is 44% below median its historical median of 15.92. Over the past decade, Cryofocus Medtech (Shanghai) Co's PB Ratio has ranged from 8.47 to 29.52. According to the industry distribution chart, Cryofocus Medtech (Shanghai) Co ranks #706 out of 784 companies in the Medical Devices & Instruments industry, placing it in the top 90.1%.
Is Cryofocus Medtech (Shanghai) Co's PB Ratio too high?
Cryofocus Medtech (Shanghai) Co's current PB Ratio of 8.97 is 44% below median its 10-year median of 15.92. Over the past 10 years, this metric has ranged from a low of 8.47 to a high of 29.52. The Medical Devices & Instruments industry median PB Ratio is 2.13. Cryofocus Medtech (Shanghai) Co's value of 8.97 is 321.1% above this industry median. Based on the distribution chart, Cryofocus Medtech (Shanghai) Co ranks #706 out of 784 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Cryofocus Medtech (Shanghai) Co has a GF Score™ of 61/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cryofocus Medtech (Shanghai) Co's PB Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Cryofocus Medtech (Shanghai) Co ranks #706 out of 784 companies for PB Ratio. This places Cryofocus Medtech (Shanghai) Co in the lower half of its industry. The industry median PB Ratio is 2.13. Cryofocus Medtech (Shanghai) Co's value of 8.97 is 321.1% above this benchmark. Historically, Cryofocus Medtech (Shanghai) Co's own PB Ratio has ranged from 8.47 to 29.52 over the past decade. While the company's 10-year median is 15.92 vs. the industry median of 2.13, Cryofocus Medtech (Shanghai) Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Devices & Instruments company?
The median PB Ratio among Medical Devices & Instruments companies is 2.13, based on 784 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cryofocus Medtech (Shanghai) Co's current PB Ratio of 8.97 is 321.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Cryofocus Medtech (Shanghai) Co and its competitors. For the Medical Devices & Instruments industry, the median PB Ratio is 2.13 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cryofocus Medtech (Shanghai) Co's current PB Ratio is 8.97, which is 44% below median its own 10-year median of 15.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cryofocus Medtech (Shanghai) Co stock overvalued right now?
Based on GuruFocus' analysis, Cryofocus Medtech (Shanghai) Co (HKSE:06922) is currently considered Possible Value Trap. The stock's GF Value™ is HK$21.01, compared to a current price of HK$2.79 — trading 86.7% below its estimated fair value. The current PB Ratio is 8.97, which is 44% below median its 10-year median of 15.92 and 321.1% above the Medical Devices & Instruments industry median of 2.13. Cryofocus Medtech (Shanghai) Co's overall GF Score™ is 61/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Cryofocus Medtech (Shanghai) Co (HKSE:06922), the current PB Ratio is 8.97 as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cryofocus Medtech (Shanghai) Co (HKSE:06922) Overvalued in 2026?
Based on GuruFocus' analysis, Cryofocus Medtech (Shanghai) Co stock appears to be undervalued.
The current stock price of HK$2.79 is trading 86.7% below its estimated GF Value™ of HK$21.01.
GuruFocus considers Cryofocus Medtech (Shanghai) Co to be Possible Value Trap.
Key valuation signals for HKSE:06922:
PB Ratio: 8.97 (44% below median its 10-year median of 15.92)
GF Value™: HK$21.01 vs. price of HK$2.79 (86.7% below fair value)
Industry Position: 321.1% above the Medical Devices & Instruments median (#706 of 784)
No single metric tells the full story. See the HKSE:06922 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cryofocus Medtech (Shanghai) Co Ltd is a medical device company engaged in the research and development, manufacture, and sale of cryoablation minimally invasive interventional treatment technology and related medical products. The company uses liquid nitrogen as the main cryogenic source for cryotherapy systems by leveraging liquid nitrogen cryoablation technology and flexible catheter technology. The products offered by the company include: Bladder Cryoablation System, Pulmonary Nodule Localization Needle, and Endoscopic Clip for Anastomosis, among others. Geographically, the company's revenue is generated from the sale of medical consumables and devices in the Chinese Mainland.
61GF Score
Get the complete analysis for HKSE:06922
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:06922 has been successfully added to your 
